Literature DB >> 11333904

Biology of E1-deleted adenovirus vectors in nonhuman primate muscle.

P W Zoltick1, N Chirmule, M A Schnell, G P Gao, J V Hughes, J M Wilson.   

Abstract

Adenovirus vectors have been studied as vehicles for gene transfer to skeletal muscle, an attractive target for gene therapies for inherited and acquired diseases. In this setting, immune responses to viral proteins and/or transgene products cause inflammation and lead to loss of transgene expression. A few studies in murine models have suggested that the destructive cell-mediated immune response to virally encoded proteins of E1-deleted adenovirus may not contribute to the elimination of transgene-expressing cells. However, the impact of immune responses following intramuscular administration of adenovirus vectors on transgene stability has not been elucidated in larger animal models such as nonhuman primates. Here we demonstrate that intramuscular administration of E1-deleted adenovirus vector expressing rhesus monkey erythropoietin or growth hormone to rhesus monkeys results in generation of a Th1-dependent cytotoxic T-cell response to adenovirus proteins. Transgene expression dropped significantly over time but was still detectable in some animals after 6 months. Systemic levels of adenovirus-specific neutralizing antibodies were generated, which blocked vector readministration. These studies indicate that the cellular and humoral immune response generated to adenovirus proteins, in the context of transgenes encoding self-proteins, hinders long-term transgene expression and readministration with first-generation vectors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11333904      PMCID: PMC114928          DOI: 10.1128/JVI.75.11.5222-5229.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: biological efficacy study.

Authors:  J F Engelhardt; R H Simon; Y Yang; M Zepeda; S Weber-Pendleton; B Doranz; M Grossman; J M Wilson
Journal:  Hum Gene Ther       Date:  1993-12       Impact factor: 5.695

2.  Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver.

Authors:  J F Engelhardt; X Ye; B Doranz; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

3.  Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression.

Authors:  Y Dai; E M Schwarz; D Gu; W W Zhang; N Sarvetnick; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

4.  Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice.

Authors:  T Ragot; N Vincent; P Chafey; E Vigne; H Gilgenkrantz; D Couton; J Cartaud; P Briand; J C Kaplan; M Perricaudet
Journal:  Nature       Date:  1993-02-18       Impact factor: 49.962

5.  Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene.

Authors:  N Vincent; T Ragot; H Gilgenkrantz; D Couton; P Chafey; A Grégoire; P Briand; J C Kaplan; A Kahn; M Perricaudet
Journal:  Nat Genet       Date:  1993-10       Impact factor: 38.330

Review 6.  The potential for gene therapy in Duchenne muscular dystrophy and other genetic muscle diseases.

Authors:  G Karpati; G Acsadi
Journal:  Muscle Nerve       Date:  1993-11       Impact factor: 3.217

Review 7.  Adenovirus-mediated in vivo gene transfer.

Authors:  S L Brody; R G Crystal
Journal:  Ann N Y Acad Sci       Date:  1994-05-31       Impact factor: 5.691

8.  MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses.

Authors:  Y Yang; H C Ertl; J M Wilson
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

Review 9.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

10.  Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis.

Authors:  Y Yang; F A Nunes; K Berencsi; E Gönczöl; J F Engelhardt; J M Wilson
Journal:  Nat Genet       Date:  1994-07       Impact factor: 38.330

View more
  7 in total

1.  Characterization of a permissive epitope insertion site in adenovirus hexon.

Authors:  Michael J McConnell; Xavier Danthinne; Michael J Imperiale
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  Plasmid DNA vaccine-elicited cellular immune responses limit in vivo vaccine antigen expression through Fas-mediated apoptosis.

Authors:  John R Greenland; Ralf Geiben; Sharmistha Ghosh; William A Pastor; Norman L Letvin
Journal:  J Immunol       Date:  2007-05-01       Impact factor: 5.422

Review 3.  Progress and problems when considering gene therapy for GSD-II.

Authors:  A Kiang; A Amalfitano
Journal:  Acta Myol       Date:  2007-07

Review 4.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

5.  T cells cause acute immunopathology and are required for long-term survival in mouse adenovirus type 1-induced encephalomyelitis.

Authors:  Martin L Moore; Corrie C Brown; Katherine R Spindler
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

Review 6.  Emerging strategies for cell and gene therapy of the muscular dystrophies.

Authors:  Lindsey A Muir; Jeffrey S Chamberlain
Journal:  Expert Rev Mol Med       Date:  2009-06-25       Impact factor: 5.600

7.  Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations.

Authors:  Ignazio Maggio; Luca Stefanucci; Josephine M Janssen; Jin Liu; Xiaoyu Chen; Vincent Mouly; Manuel A F V Gonçalves
Journal:  Nucleic Acids Res       Date:  2016-01-13       Impact factor: 16.971

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.